Source:http://linkedlifedata.com/resource/pubmed/id/21224345
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2011-1-17
|
pubmed:abstractText |
Expression of microRNA genes is profoundly altered in cancer but their role in the development of androgen-independent prostate cancer has received limited attention as yet. In this study, we report a functional impact in prostate cancer cells for overexpression of the microRNA miR-616, which occurred consistently in cells that were androgen-independent (AI) versus androgen-dependent (AD). miR-616 overexpression was confirmed in malignant prostate tissues as opposed to benign prostate specimens. Stable miR-616 overexpression in LNCaP cells by a lentiviral-based approach stimulated AI prostate cancer cell proliferation in vitro whereas concomitantly reducing androgen-induced cell growth. More importantly, miR-616 overexpressing LNCaP cells overcame castration resistance as shown by an enhanced ability to proliferate in vivo after bilateral orchiectomy. Conversely, antagonizing miR-616 in AI prostate cancer cells yielded opposite effects. Microarray profiling and bioinformatics analysis identified the tissue factor pathway inhibitor TFPI-2 mRNA as a candidate downstream target of miR-616. In support of this candidacy, we documented interactions between miR-616 and the 3'UTR of TFPI-2 and determined TFPI-2 expression to be inversely correlated to miR-616 in a series of prostate cell lines and clinical specimens. Notably, reexpression of TFPI-2 in LNCaP cells with stable miR-616 overexpression rescued the AD phenotype, as shown by a restoration of androgen dependence and cell growth inhibition. Taken together, our findings define a functional involvement for miR-616 and TFPI-2 in the development and maintenance of androgen-independent prostate cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1538-7445
|
pubmed:author | |
pubmed:copyrightInfo |
© 2011 AACR.
|
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
71
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
583-92
|
pubmed:meshHeading |
pubmed-meshheading:21224345-Androgens,
pubmed-meshheading:21224345-Animals,
pubmed-meshheading:21224345-Cell Growth Processes,
pubmed-meshheading:21224345-Cell Line, Tumor,
pubmed-meshheading:21224345-Glycoproteins,
pubmed-meshheading:21224345-Humans,
pubmed-meshheading:21224345-Male,
pubmed-meshheading:21224345-Mice,
pubmed-meshheading:21224345-Mice, Nude,
pubmed-meshheading:21224345-MicroRNAs,
pubmed-meshheading:21224345-Neoplasms, Hormone-Dependent,
pubmed-meshheading:21224345-Orchiectomy,
pubmed-meshheading:21224345-Prostatic Hyperplasia,
pubmed-meshheading:21224345-Prostatic Neoplasms
|
pubmed:year |
2011
|
pubmed:articleTitle |
MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2.
|
pubmed:affiliation |
Department of Pathology, The University of Hong Kong, Hong Kong. stefma@hkucc.hku.hk
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|